Cost-effectiveness of a new rotavirus vaccination program in Pakistan: A decision tree model

被引:16
|
作者
Patel, Hiten D. [1 ,2 ]
Roberts, Eric T. [3 ]
Constenla, Dagna O. [4 ]
机构
[1] Johns Hopkins Med Inst, James Buchanan Brady Urol Inst, Baltimore, MD 21205 USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA
[3] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA
[4] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA
关键词
Rotavirus; Gastroenteritis; Cost-effectiveness; Vaccination; Pakistan; GLOBAL BURDEN; DISEASE; CHILDREN; GASTROENTERITIS; SURVEILLANCE; EFFICACY; HEALTH; IMPACT; IMMUNIZATION; STRATEGIES;
D O I
10.1016/j.vaccine.2013.10.022
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Rotavirus gastroenteritis places a significant health and economic burden on Pakistan. To determine the public health impact of a national rotavirus vaccination program, we performed a cost-effectiveness study from the perspective of the health care system. Methods: A decision tree model was developed to assess the cost-effectiveness of a national vaccination program in Pakistan. Disease and cost burden with the program were compared to the current state. Disease parameters, vaccine-related costs, and medical treatment costs were based on published epidemiological and economic data, which were specific to Pakistan when possible. An annual birth cohort of children was followed for 5 years to model the public health impact of vaccination on health-related events and costs. The cost-effectiveness was assessed and quantified in cost (2012 US$) per disability-adjusted life-year (DALY) averted and cost per death averted. Sensitivity analyses were performed to assess the robustness of the incremental cost-effectiveness ratios (ICERs). Results: The base case results showed vaccination prevented 1.2 million cases of rotavirus gastroenteritis, 93,000 outpatient visits, 43,000 hospitalizations, and 6700 deaths by 5 years of age for an annual birth cohort scaled from 6% current coverage to DPT3 levels (85%). The medical cost savings would be US$1.4 million from hospitalizations and US$200,000 from outpatient visit costs. The vaccination program would cost US$35 million at a vaccine price of US$5.00. The ICER was US$149.50 per DALY averted or US$4972 per death averted. Sensitivity analyses showed changes in case-fatality ratio, vaccine efficacy, and vaccine cost exerted the greatest influence on the ICER. Conclusions: Across a range of sensitivity analyses, a national rotavirus vaccination program was predicted to decrease health and economic burden due to rotavirus gastroenteritis in Pakistan by similar to 40%. Vaccination was highly cost-effective in this context. As discussions of implementing the intervention intensify, future studies should address affordability, efficiency, and equity of vaccination introduction. 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6072 / 6078
页数:7
相关论文
共 50 条
  • [41] The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales
    Atkins, Katherine E.
    Shim, Eunha
    Carroll, Stuart
    Quilici, Sibilia
    Galvani, Alison P.
    VACCINE, 2012, 30 (48) : 6766 - 6776
  • [42] Projected cost-effectiveness of rotavirus vaccination for children in Asia
    Podewils, LJ
    Antil, L
    Hummelman, E
    Bresee, J
    Parashar, UD
    Rheingans, R
    JOURNAL OF INFECTIOUS DISEASES, 2005, 192 : S133 - S145
  • [43] Cost effectiveness evaluation of a rotavirus vaccination program in Argentina
    Garcia Marti, Sebastian
    Alcaraz, Andrea
    Valanzasca, Pilar
    McMullen, Mercedes
    Standaert, Baudouin
    Garay, Ulises
    Lepetic, Alejandro
    Gomez, Jorge
    VACCINE, 2015, 33 (42) : 5684 - 5690
  • [44] COST EFFECTIVENESS EVALUATION OF A ROTAVIRUS VACCINATION PROGRAM IN ARGENTINA
    Garcia Marti, S.
    Alcaraz, A.
    Valanzasca, P.
    Mc Mullen, M.
    Standaert, A.
    Garay, U.
    Lepetic, A. C.
    Gomez, J. A.
    VALUE IN HEALTH, 2013, 16 (07) : A709 - A709
  • [45] Effectiveness and cost-effectiveness of pediatric rotavirus vaccination in British Columbia: A model-based evaluation
    Fisman, David N.
    Chan, Christina H.
    Lowcock, Elizabeth
    Naus, Monika
    Lee, Victoria
    VACCINE, 2012, 30 (52) : 7601 - 7607
  • [46] TRIVAC decision-support model for evaluating the cost-effectiveness of Haemophilus influenzae type b, pneumococcal and rotavirus vaccination
    Clark, Andrew
    Jauregui, Barbara
    Griffiths, Ulla
    Janusz, Cara B.
    Bolanos-Sierra, Brenda
    Hajjeh, Rana
    Andrus, Jon K.
    Sanderson, Colin
    VACCINE, 2013, 31 : C19 - C29
  • [47] Cost-effectiveness of adding new rotavirus vaccines to the national immunization program in Kyrgyzstan
    Flem, E. T.
    Latipov, R.
    Nurmativ, Z. S.
    Xue, Y.
    Kasymbekova, K. T.
    Rheingans, R.
    VACCINE, 2008,
  • [48] Cost-effectiveness and potential impact of rotavirus vaccination in the United States
    Widdowson, Marc-Alain
    Meltzer, Martin I.
    Zhang, Xinzhi
    Bresee, Joseph S.
    Parashar, Umesh D.
    Glass, Roger I.
    PEDIATRICS, 2007, 119 (04) : 684 - 697
  • [49] Conclusion on cost-effectiveness of rotavirus vaccination highly dependent on assumptions
    Goossens, Lucas
    Standaert, Baudouin
    Hartwig, Nico
    Hovels, Anke M.
    Al, Maiwenn J.
    VACCINE, 2009, 27 (19) : 2531 - 2532
  • [50] Cost-effectiveness estimates of vaccination against rotavirus in Piedmont, Italy
    Gualano, Maria R.
    Thomas, Robin
    Gili, Renata
    Scaioli, Giacomo
    Voglino, Gianluca
    Zotti, Carla
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2018, 11 (06) : 867 - 872